Own the Scale or Share It: This Season Rewards Whoever Controls the Terms
Halozyme, Protagonist and BeOne show that the best results come from owning scale or from holding well-written claims on someone else's. Leaders should audit which they have.
Two routes to the same strong quarter
Third-quarter results offer two ways to build a good earnings story, and the less discussed one is the more instructive. BeOne is the textbook case of owned scale. It reported $1.9 billion in revenue, up 34%, with BRUKINSA at $1.4 billion, also up 34%. It raised full-year revenue guidance to $6.9 to $7.0 billion. The company carries the cost, the risk and the reward of its own commercial machine.
Halozyme is the opposite model, and its numbers are as striking. Total revenue rose 39% to $493 million, and royalty revenue rose 44% to $341 million. Full-year guidance now points to adjusted EBITDA growth of 89% to 96% and non-GAAP EPS growth of 111% to 118%, against total revenue growth of 33% to 38%. Profit is growing far faster than sales because Halozyme earns on partners' volume rather than funding that volume itself. It also expanded ENHANZE agreements with three current partners and advanced three programs into Phase 1.
Our view is that the industry still undervalues the second route. Carrying a partner's product does not diminish a company. In this season's data, a well-structured claim on someone else's commercial success can convert growth to profit as efficiently as owned scale, and sometimes more so.
The partner's economics, up close
Protagonist shows the same logic from the development side. FDA approval of MIMRYLO triggered $275 million in payments to the company. ICOTYDE is launching strongly under its collaboration with Johnson & Johnson. Protagonist ended September with $834.6 million in cash, cash equivalents and marketable securities. It has announced a $300 million share repurchase program and plans a Phase 2b program for its oral IL-17 antagonist PN-881 in early Q1 2027.
The point is not that Protagonist avoided work. It did the science, and its CEO calls the approvals the result of years of disciplined execution. The point is that its contract turned that work into cash at the moment of regulatory success. Nobody had to build a commercial infrastructure first.
Prothena is the quieter version. Its net cash used in operating and investing activities was $12.0 million in the quarter, and it ended with $272.2 million in cash and restricted cash. Novo's post hoc analyses of coramitug in ATTR-CM keep the asset's case alive while a partner carries the late-stage burden. Prothena's collaboration on CYTOPE is also meant to widen its options. The balance sheet holds up because the risk is shared.
The strongest counter-argument
The objection is serious. A partner model means you do not control the launch. Halozyme's royalties depend on partners' products continuing to sell. Protagonist's $275 million is a milestone, not a recurring run-rate, and it will not repeat on the same asset. Prothena's progress is real but has not yet produced revenue. BeOne, meanwhile, is growing 34% with an owned product and has raised guidance, which suggests control still pays. Viatris and Biogen, by contrast, show what the owner's path can cost: both reported GAAP losses in the quarter, driven in Biogen's case by transaction-related charges.
That is fair, and it is why we are not arguing that partnering beats owning. We are arguing that the terms matter more than the label. A royalty on a growing franchise, or a milestone tied to approval, is an earnings stream with a known trigger. An owned launch is an earnings stream with a known cost. Neither is safe by default.
What this means for the boardroom
Too many strategy discussions still begin with whether to build or to partner. This season suggests a better starting question: where in the value chain do we hold a claim, and who controls whether it pays? Companies with strong claims on partners' volume are reporting profit growth that outpaces revenue. Companies with strong owned franchises are raising guidance. The weak spot is the middle ground, where a company owns the costs but not the upside.
This is an editorial position, not a forecast, and the data covers one quarter at six companies. But the pattern is consistent enough that executives should test their own portfolios against it.
The Editor, CompePharma
What leaders should do
- Map every asset by who funds the launch, who controls its pace, and where your claim sits in the revenue stream. Then check whether the economics match the risk you carry.
- Treat partnership terms as earnings architecture. Royalty rates, milestone triggers and expansion rights shape profit growth as much as the underlying product does.
- Do not mistake milestones for run-rate. Plan with one-time approval payments as funding for the next program, and judge partner-dependent streams by the growth of the partners' products.
Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. It can contain errors; check the sources. Not investment advice.
The second act is where this quarter's money was made
The strongest results this season came from extending assets already in market, through new labels, formulations and royalties, rather than from unproven launches. That strategy has a ceiling.
A fee schedule rate is not a durable price: coverage is the real asset
Medicare's full-rate payment for EsoGuard is a milestone, but case-by-case coverage and a pending reconsideration show why payer access, not list price, decides the economics.
Plan the exit before the readout: strategic alternatives shouldn't start after a miss
Longeveron, Theriva and Silence show how much optionality depends on when boards start thinking about the endgame. The best time is before the data arrive.